Profile data is unavailable for this security.
About the company
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
- Revenue in USD (TTM)174.33m
- Net income in USD-197.71m
- Incorporated2013
- Employees283.00
- LocationRhythm Pharmaceuticals Inc222 Berkeley Street, 12th FloorBOSTON 02116United StatesUSA
- Phone+1 (857) 264-4280
- Fax+1 (857) 264-4299
- Websitehttps://rhythmtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.41bn | 315.00 | 100.32 | 6.34 | 91.15 | 5.70 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.49bn | 157.00 | -- | 158.15 | -- | 50.49 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 3.66bn | 68.00 | 89.49 | 3.85 | 44.21 | 14.57 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| ADMA Biologics Inc | 488.56m | 209.45m | 3.87bn | 677.00 | 19.21 | 9.00 | 17.82 | 7.93 | 0.8476 | 0.8476 | 1.98 | 1.81 | 1.02 | 1.20 | 5.20 | 721,652.90 | 43.67 | -2.99 | 48.83 | -3.39 | 54.71 | 34.09 | 42.87 | -4.56 | 3.65 | 26.62 | 0.1438 | -- | 65.15 | 70.79 | 800.00 | -- | 17.60 | -- |
| Corcept Therapeutics Inc | 741.17m | 106.11m | 4.29bn | 500.00 | 46.09 | 6.79 | 40.04 | 5.79 | 0.8858 | 0.8858 | 6.19 | 6.01 | 0.9219 | 1.31 | 11.46 | 1,482,344.00 | 13.20 | 20.07 | 16.21 | 23.01 | 98.19 | 98.53 | 14.32 | 24.89 | 3.07 | -- | 0.00 | 0.00 | 39.94 | 17.11 | 33.04 | 8.44 | 14.83 | -- |
| TG Therapeutics Inc | 531.90m | 447.47m | 4.58bn | 374.00 | 10.37 | 7.37 | 10.22 | 8.60 | 2.78 | 2.78 | 3.29 | 3.91 | 0.6603 | 0.6733 | 2.79 | 1,573,663.00 | 55.55 | -42.93 | 67.33 | -52.55 | 85.34 | -- | 84.13 | -142.45 | 2.89 | 3.77 | 0.2878 | -- | 40.80 | 364.59 | 84.52 | -- | -19.24 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.62bn | 8.10k | 889.83 | -- | 15.50 | 1.57 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Mirum Pharmaceuticals Inc | 471.79m | -41.42m | 5.16bn | 355.00 | -- | 17.55 | -- | 10.94 | -0.8613 | -0.8613 | 9.26 | 5.69 | 0.6494 | 4.15 | 5.37 | 1,465,199.00 | -5.70 | -29.54 | -7.04 | -34.57 | 79.92 | -- | -8.78 | -92.71 | 3.16 | -22.48 | 0.5144 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
| PTC Therapeutics, Inc. | 1.78bn | 751.72m | 5.69bn | 939.00 | 8.31 | -- | 7.26 | 3.20 | 8.53 | 8.53 | 21.64 | -1.95 | 0.7932 | 1.28 | 8.83 | 1,894,728.00 | 33.51 | -26.68 | 49.97 | -34.84 | 96.83 | 93.49 | 42.25 | -74.67 | 2.26 | 6.03 | 1.07 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.57bn | 283.00 | -- | 44.12 | -- | 37.69 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 7.91bn | 275.00 | 40.92 | 6.94 | 38.67 | 21.19 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.35bn | 350.00 | 16.72 | 18.54 | 13.80 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.39bn | 683.00 | -- | 127.06 | -- | 16.73 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
Data as of Feb 11 2026. Currency figures normalised to Rhythm Pharmaceuticals Inc's reporting currency: US Dollar USD
56.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.72m | 8.57% |
| RA Capital Management LPas of 30 Sep 2025 | 5.68m | 8.51% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 5.60m | 8.40% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 5.30m | 7.94% |
| PRIMECAP Management Co.as of 30 Sep 2025 | 4.26m | 6.39% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.93m | 5.89% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.10m | 3.15% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.03m | 3.04% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 1.67m | 2.50% |
| Federated Global Investment Management Corp.as of 30 Sep 2025 | 1.53m | 2.30% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
